$47.69
-0.60%Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Last Annual Value
4.53B
3-Year CAGR
44%
5-Year CAGR
25%
10-Year CAGR
22%
| Company | Operating Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
![]() Boston Scientific Corporation NYSE:BSX | 4.53B | 21.9% | 19.4% | 16.6% | |
![]() Medtronic plc NYSE:MDT | 7.04B | 5.3% | 2.5% | 3.0% | |
![]() Pfizer Inc. NYSE:PFE | 11.71B | 10.4% | -18.5% | -3.0% | |
![]() Abbott Laboratories NYSE:ABT | 9.57B | 9.6% | -1.9% | 11.6% | |
![]() HCA Healthcare, Inc. NYSE:HCA | 12.64B | 10.2% | 7.1% | 8.4% | |
![]() Gilead Sciences, Inc. NASDAQ:GILD | 10.02B | 7.8% | -2.5% | -5.2% | |
![]() McKesson Corporation NYSE:MCK | 6.16B | 6.1% | 6.3% | 5.3% | |
![]() Danaher Corporation NYSE:DHR | 6.42B | -3.6% | -5.2% | 6.2% | |
![]() Amgen Inc. NASDAQ:AMGN | 9.96B | 5.5% | 1.5% | -0.4% | |
![]() Stryker Corporation NYSE:SYK | 5.04B | 10.8% | 9.1% | 10.2% |
Continue your BSX research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.